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Abstract 
Background: Pancreatic acinar cell carcinoma (PACC) is a rare malignancy, accounting for <1 % of all pancreatic neo‑
plasms. Very few retrospective studies are available to help guide management. We previously reported the case of a 
patient with metastatic PACC who achieved prolonged survival following doxorubicin treatment. Personalized treat‑
ment was based on molecular and in vitro data collected from primary cells developed from their liver metastasis. We 
now report the characterization of a patient derived tumor xenograft (PDTX) mouse model that originated from this 
patient’s PACC liver metastasis.
Methods: Fragments of biopsy tissue (5 mm3) from PACC liver metastasis were implanted into athymic nude mice. 
Tumors were grown and passaged from the host mice into new mice to be tested for therapeutic response. Immuno‑
histochemical (IHC) biomarkers were used to confirm that the PDTX model represents human PACC. The antitumor 
activities of multiple drugs (5‑FU, irinotecan, oxaliplatin, gemcitabine, bevacizumab, erlotinib, doxorubicin and 
imatinib) were tested. Tumor size was measured over 74 days or until they reached an endpoint volume of ~800 mm3. 
Tests to measure serum lipase levels and histological analyses of tumor tissues were also conducted to assess PACC 
progression and re‑differentiation.
Results: The model presented here expresses the same IHC markers found in human PACC. In the chemotherapy 
study, oxaliplatin produced a prolonged durable growth response associated with increased apoptosis, decreased 
serum lipase levels and increased healthy acinar cells. Bevacizumab also produced a significant growth response, but 
the effect was not prolonged as demonstrated by oxaliplatin treatment. The other chemotherapies had moderate 
to little effect, particularly after treatment ceased. Mutations in DNA repair genes are common in PACC and increase 
tumor susceptibility to oxaliplatin. To explore this we performed IHC and found no nuclear expression of BRCA2 in 
our model, indicating a mutation affecting nuclear localization. Gene sequencing confirms BRCA2 has a homozygous 
gene deletion on Exon 10, which frequently causes a protein truncation.
Conclusions: In summary, we report the development and characterization of the first and only preclinical PACC 
PDTX model. Here we show sustained anti‑tumor activity of single agent oxaliplatin, a compound that is more effec‑
tive in tumors that harbor mutations in DNA repair genes. Our data shows that BRCA2 is mutated in our PACC model, 
which could contribute to the oxaliplatin sensitivity observed. Further studies on this rare PACC model can serve to 
elucidate other novel therapies, biomarkers, and molecular mechanisms of signaling and drug resistance.
© 2016 Hall et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://
creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided 
you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate 
if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/
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Background
Pancreatic acinar cell carcinoma (PACC) is a rare, fre-
quently lethal disease, accounting for less than 1  % of 
all pancreatic neoplasms tumors [1–4]. A retrospective 
series of 672 patients with PACC reported a 47 months 
median survival [5]. A review of patients seen at Memo-
rial Sloan Kettering from 1981 to 2001 found that 
the median survival of patients with metastasis was 
14 months as compared to 38 months in the absence of 
metastasis [1]. A follow up retrospective study reviewing 
patients seen from 2000 to 2011 found a median survival 
of 57 months for patients with localized resected tumors 
and a 19 months median survival in patients with meta-
static disease [6].
Patients with PACC frequently present with abdomi-
nal pain and bloating as the dominant symptoms, and in 
some cases their initial clinical diagnosis given was acute 
pancreatitis [1, 7, 8]. Elevation of serum lipase levels can 
be associated with systemic fat necrosis, a significant 
cause of morbidities in PACC patients [9–12]. However, 
elevated serum lipase and amylase levels can be seen in 
both PACC and acute pancreatitis leading to difficulties 
in establishing a correct diagnosis [13, 14]. Reliable mark-
ers of PACC have been slowly emerging such as carci-
noembryonic antigen (CEA) [15], cytokeratin 18 (CK18) 
[16] and B-cell lymphoma/leukemia 10 (BCL10) [17, 18] 
allowing us to distinguish acinar cell carcinoma from 
normal acinar cells or other pancreatic cancers through 
histology.
The genetic and molecular abnormalities that lead to 
PACC have not been fully identified. Recent studies have 
found that genes regulating DNA repair may be mutated 
in PACC patients. DNA repair mutations were noted in 
45 % of PACC tumors, BRCA2 being the most common 
gene, followed by BRCA1 and ATM20 [3, 6, 19]. Previ-
ously, we reported on a case of a PACC patient receiv-
ing personally designed treatments based on the genetic 
and molecular profiles of his tumor [20]. We cultured 
the patient’s tumor biopsies into primary cell lines and 
treated them with different chemotherapy agents [20]. 
The outcome was that a DNA replication inhibitor, (iri-
notecan), a DNA intercalating agent and transcription 
inhibitor (doxorubicin), and a tyrosine kinase inhibitor 
(imatinib) were among the most effective agents against 
his tumor cells in cell culture [20]. As a result of the 
observations seen in  vitro, liposomal doxorubicin was 
administered and the patient had evidence of a sustained 
clinical response throughout the treatment regimen [20].
Here, we report the characterization of a PACC patient 
derived tumor xenograft (PDTX) mouse model (PA-018) 
from the patient’s tumor biopsy. With the use of PA-018, 
multiple chemotherapies (5-FU, oxaliplatin, gemcitabine, 
liposomal doxorubicin) and targeted agents (irinotecan, 
bevacizumab, erlotinib, imatinib) were tested in vivo. Of 
the therapies tested, oxaliplatin was the most promising 
and demonstrated sustained antitumor activity after only 
3  weekly treatments. Therefore, evaluation of potential 
effective treatments using this PDTX model is a viable 
technology that may facilitate the discovery of effective 
treatments against this rare tumor. We provide the first 




Biopsy tissue from PACC liver metastasis was implanted 
subcutaneously into two 5 week old anesthetized athymic 
nude female mice strain #069 (Harlan Laboratories, 
Indianapolis, IN) under IACUC approved procedures. 
Implanted tumors were harvested and frozen as 5  mm3 
fragments in 10  % DMSO-DMEM media and multiple 
“passages” were continued in athymic nude mice. Apply-
ing this technique to the patient’s tumor has created a 
renewable source of PACC tissue and a representative 
in vivo model to test promising drugs. This PACC PDTX 
model is available at Charles Rivers (CR) Discovery Ser-
vices (Morrisville, NC).
In vivo implantation and tumor growth
For the in vivo study, 6 week old female athymic nude 
mice strain #490 (CR Discovery Services) were sub-
cutaneously implanted with 5  mm3 tumor fragments 
into the right flanks. They were fed ad libitum NIH 31 
Modified and Irradiated Lab Diet® consisting of 18.0 % 
crude protein, 5  % crude fat, and 5  % crude fiber and 
housed on irradiated Enrich-o’cobs™ Laboratory Ani-
mal Bedding in static microisolators on a 12-hour light 
cycle at 20–22  °C (68–72  °F) and at 40–60  % humid-
ity. CR Discovery Services specifically complies with 
the recommendations of the Guide for Care and Use 
of Laboratory Animals with respect to restraint, hus-
bandry, surgical procedures, feed and fluid regulation, 
and veterinary care. The animal care and use program 
at CR Discovery Services is accredited by the Associa-
tion for Assessment and Accreditation of Laboratory 
Animal Care International, which assures compliance 
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with accepted standards for the care and use of labora-
tory animals.
Fifty-five days later (~14 weeks old), designated as day 1 
of the study, mice were sorted into treatment groups with 
individual tumor volumes ranging from 75 to 245  mm3 
and group mean tumor volumes of 164–170 mm3. Tumor 
size, in mm3, was calculated from:
where w is the width and l is the length, in mm, of the 
tumor. Tumor weight was estimated with the assumption 
that 1 mg is equivalent to 1 mm3 of tumor volume.
Test articles and dosing regimens
The following therapies were prepared on each day of 
dosing as follows: 5-Fluorouracil or 5-FU (TEVA Phar-
maceuticals, 50  mg/mL, Lot# 6102655) was diluted to 
10  mg/mL with sterile 5  % dextrose in water (D5  W) 
and administered at 100  mg/kg intra-peritoneal (ip) 
weekly for 3  weeks. Irinotecan solution for injection 
(Sandoz Pharmaceuticals, Inc., 20 mg/mL, Lot# CF0165) 
was diluted to 10  mg/mL with D5  W and administered 
at 100  mg/kg ip once weekly for 3  weeks. An aliquot 
of oxaliplatin stock (Eloxatin®, Sanofi Aventis, 5  mg/
mL, Lot# CH630) was diluted to 1  mg/mL with ster-
ile D5  W, which provided a 10  mg/kg dosage that was 
administered ip once weekly for 3  weeks. Gemcitabine 
(Gemzar®, Eli Lilly, Lot# A906313D) was reconstituted to 
12 mg/mL with sterile saline (0.9 % NaCl) and 120 mg/
kg was administered ip daily every 3  days for a total of 
four doses. An aliquot of Bevacizumab stock (Avastin®, 
Genentech, Lot# 956583, 25  mg/mL) was diluted to 
0.5  mg/mL with saline, which provided a 5  mg/kg dos-
age that was administered ip twice weekly for five weeks. 
Liposomal doxorubicin (Doxil, Sequus Pharmaceuticals, 
Inc., 2  mg/mL, Lot# 1107161) was diluted to 0.3  mg/
mL in saline, which provided a 3 mg/kg dosage that was 
administered intravenously (i.v.) once weekly for 3 weeks. 
Imatinib mesylate (Gleevec®, Novartis Pharmaceuticals 
Corp, 100 mg tablets) dosing suspensions were prepared 
by resuspending the required amount of tablets in ster-
ile water for injection to yield a final concentration of 
10 mg/mL and then administered orally (po) at 100 mg/
kg once daily for 28 days. Dosing suspensions of erlotinib 
(Tarceva®, OSI Pharmaceuticals, Inc., Lot# 1121701CW, 
100  mg tablets) were prepared by resuspending the 
required amount of tablets in 1 % CMC : 0.1 % Tween80 
in sterile water to produce a final concentration of 8 mg/
mL and then administered orally at of 80  mg/kg once 
daily for 15  days. In all groups, the dosing volume of 
10 mL/kg (0.2 mL/20 g mouse) was scaled to the weight 







Tumors were measured twice weekly using calipers. Each 
animal was euthanized when its neoplasm reached the 
endpoint volume of 800 mm3 or day 74, whichever came 
first. The time-to-endpoint (TTE) for each mouse was 
calculated for each endpoint by the following equation:
where TTE is expressed in days, endpoint volume is 
expressed in mm3, b is the intercept, and m is the slope 
of the line obtained by linear regression of a log-trans-
formed tumor growth data set. The data set is comprised 
of the first observation that exceeded the endpoint vol-
ume used in analysis and the three consecutive observa-
tions that immediately preceded the attainment of this 
endpoint volume. Any animal that did not reach end-
point was euthanized at the end of the study and assigned 
a TTE value equal to the last day of the study. Any animal 
determined to have died from treatment-related (TR) 
causes was to be assigned a TTE value equal to the day of 
death. Any animal that died from non-treatment-related 
(NTR) causes was excluded from the analysis.
Treatment efficacy was determined from tumor growth 
delay (TGD), which is defined as the increase in the 
median TTE for a treatment group compared to the con-
trol group:
expressed in days, or as a percentage of the median TTE 
of the control group:
where T is the median TTE for a treatment group, C is 
the median TTE for control Group 1.
Toxicity
Test animals were observed frequently for any overt signs 
of adverse, treatment-related side effects, and clinical 
signs of toxicity were recorded. Test animals were also 
weighed twice weekly and any animal that exceeded the 
limits for acceptable body weight (BW) loss was eutha-
nized. Dosing was suspended in any group that exceeded 
the limits for acceptable mean BW loss. If mean BW 
recovered, then dosing may be resumed in that group, 
but at a lower dosage or less frequent dosing schedule. 
Acceptable toxicity for the maximum tolerated dose 
(MTD) was defined as group mean BW loss of less than 
20 % during the test, and no more than 10 % TR mortal-
ity. A death was classified as TR if it was attributable to 
treatment side effects as evidenced by clinical signs and/
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period or within 14  days of the last dose. A death was 
classified as NTR if there is no evidence that the death 
was related to treatment side effects.
Statistical analysis and graphical presentations
Prism (GraphPad) for Windows 6.02 was used for all sta-
tistical analysis and graphical presentations. The logrank 
test was employed to assess the significance of the dif-
ference between the overall survival experiences of two 
groups. The logrank test analyzed the individual TTEs 
for all animals in a group, except those lost to the study 
due to NTR deaths. The two-tailed statistical analysis was 
conducted at P = 0.05. Prism reports results as non-sig-
nificant (ns) at P > 0.05, significant (symbolized by “*”) at 
0.01 < P ≤ 0.05, very significant (“**”) at 0.001 < P ≤ 0.01 
and extremely significant (“***”) at P ≤  0.001. Since the 
logrank test is a test of significance and does not provide 
an estimate of the size of the difference between groups, 
all levels of significance are reported as either signifi-
cant or non-significant within the context of this report. 
When an animal exited the study due to tumor size or TR 
death, the final tumor volume recorded for the animal 
was included with the data used to calculate the median 
volume at subsequent time points. Tumor growth curves 
were truncated when the tumors in more than 50  % of 
the assessable animals in a group have grown to the end-
point volume or treatment exceeded the MTD (≥20  % 
body weight loss or >10 % TR related mortality).
Serum lipase
Blood was collected sublingually under no anesthesia at 
pre-dose and day 15 for n = 5 mice per group in EDTA 
collection tubes. Serum was collected and analyzed by 
IDEXX laboratories (Westbrook, Maine) for serum lipase 
levels.
Immunohistochemistry (IHC) and immunofluorescence (IF)
Formalin-fixed tissues were collected and embedded into 
paraffin. A tissue microarray (TMA) was constructed for 
all tumor tissues from each of the treatment groups and 
used for IHC analysis. TMA tissues were cut into 5 mm 
sections, deparaffinized, hydrated, antigen retrieved and 
blocked with diluent that contained Background Reduc-
ing Components (Dakocytomation, Denmark). Immu-
nostaining was done on either the TMA or PA-018 alone 
with the following: carcinoembryonic antigen (CEA), 
neuron specific enolase (NSE), Chromogranin A (CgA), 
and cytokeratin 19 (CK19) [1:100, anti-mouse with 
rodent block (Dakocytomation)]; Mist-1 [1:2000] and 
cleaved caspase-3 (CC3) [1:100 hi pH, anti-rabbit (Cell 
Signaling, Beverly, MA)]; amylase [1:1000, anti-rabbit 
(Sigma-Aldrich, St.Louis, MO)]; lipase [1:1600], BRCA1 
[1:100], and Collagen I [1:1500, anti-rabbit (Abcam, 
Cambridge, MA)]; BCL-10 [1:200, anti-rabbit] and CD31 
[1:100, anti-goat (Santa Cruz, CA)]; BRCA2 [1:500, 
anti-mouse (R&D systems)]. For IHC the Envision Dual 
Labeled Polymer kit (DakoCytomation) was used accord-
ing to the manufacturer’s instructions and then lightly 
counterstained with Gill I hematoxylin (Sigma-Aldrich) 
before dehydration and mounting. Images were obtained 
using Scanscope XT (Aperio Technologies, Vista, CA) 
and the staining of the TMA punches were scored using 
an algorithm in the Imagescope software (Aperio Tech-
nologies) created by a histologist based upon signal 
intensity (0, 1+  , 2+  , 3+) and percentage. For immu-
nofluorescence, tissue was incubated with AlexaFlour 
594-conjugated secondary antibody (Invitrogen) and 
mounted with Vectashield containing DAPI (Vector Lab-
oratories, Burlingame, CA). Images were acquired on a 
Zeiss LSM 880 confocal laser scanning microscope (Carl 
Zeiss MicroImaging, Inc, Thornwood, NY).
Gene mutation analysis
DNA from a fresh frozen sample of PA-018 was isolated 
and underwent custom capture (eArray; Agilent, Santa 
Clara, CA) of the coding region and intron/exon bounda-
ries of coding exons for BRCA2. Products from each cap-
ture reaction were sequenced on a HiSeq 2000 (Illumina, 
San Diego, CA) and analyzed as described by Couch et al. 
[21].
Results
Characterization of the PACC PDTX mouse model
PA-018, a pancreatic acinar cell carcinoma (PACC) 
PDTX mouse model, was derived from a metastatic 
liver biopsy of a patient previously described in a case 
report [20]. The histologic features of PA-018 were 
similar to those in the patient’s pancreatic primary tis-
sue (Fig. 1a). These features included a solid, acinar-like 
growth pattern by cells with undifferentiated nuclei and 
amphophilic cytoplasm. Immunohistochemistry (IHC) 
with human specific mitochondrial surface protein and 
human lamin A+C and confirmed that the xenograft 
tumor cells were of human origin (Fig. 1b). Short tandem 
repeat (STR) analysis showed that the genetic signature 
of our PDTX tumor (passage 5) closely matched (allele 
drop out was noted) the signature of the patient. The 
DNA that was used for comparison was from a sample 
taken 3 years prior to the PA-018 biopsy due to unavail-
able tissue (Additional file 1: Table S1).
IHC characterization of PA-018 showed a reduc-
tion in cytoplasmic expression of amylase and lipase 
as compared to the normal human pancreas, while 
the pancreatic acinar marker, Mist-1 [22], was widely 
expressed in the tumor tissue (Fig.  1c, panels i–
iii). PA-018 also expressed previously documented 
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Fig. 1 Characterization of the PACC PDTX mouse model. a Hemotoxylin and eosin (H&E) staining of paraffin embedded patient and PDTX PACC 
tumor tissues (magnification X20) b Immunohistochemistry (IHC) of human specific antibodies, mitochondrial surface marker and lamin A+C. c 
IHC for acinar cell markers [amylase, lipase, Mist‑1], acinar cell carcinoma markers [carcinoembryonic antigen (CEA), cytokeratin 18 (CK18), B‑cell 
lymphoma/leukemia 10 (BCL10)], ducts [cytokeratin 19 (CK19)] and neuroendocrine markers [neuron specific enolase (NSE), chromogranin A (CgA)] 
at X20 magnification. Inlays are normal human pancreas
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markers of PACC, including CEA [15], CK18 [16] and 
BCL10 [17, 18] (Fig.  1c, panels iv, vi) and had a lack 
of cytokeratin 19 (CK19) expression, a marker of ducts 
and pancreatic ductal tumors [23] (Fig.  1c, panel vii). 
Since PACC can have heterogeneous tumor popula-
tions, which include neuroendocrine derived cancer 
cells, we stained for neuroendocrine markers, such as 
neuron specific enolase (NSE) and chromogranin A 
(CgA). PA-018 was negative for NSE and CgA as com-
pared to the islet cells in normal human pancreas [24] 
(Fig. 1c, panels viii–ix).
Evaluation of different chemotherapies demonstrate 
that oxaliplatin sustains tumor growth inhibition in the 
PACC PDTX mouse model
For studies on the effects of different monotherapies, 
PA-018 was expanded and 4 mm3 tissues (passage 5) were 
ectopically implanted into flanks of athymic nude female 
mice. Therapy was implemented once tumors reached an 
average of 100  mm3. Agents tested included; DNA syn-
thesis inhibitors (5-FU, gemcitabine), a DNA alkylating 
agent (oxaliplatin), a DNA intercalating agent (liposomal 
doxorubicin), a topoisomerase inhibitor (irinotecan), an 
EGFR inhibitor (erlotinib), a c-kit inhibitor (imatinib) 
and an angiogenesis inhibitor (bevacizumab). The ration-
ale for these drug choices were based upon previous gene 
array and protein analyses performed on the patient 
tumor tissue [20]. Possible drug therapies and interac-
tions with upregulated genes include: CES2 (irinotecan), 
TOP2B (liposomal doxorubicin), and DNA repair genes 
(oxaliplatin). Proteins upregulated include EGFR (erlo-
tinib), and c-kit (imatinib) [20]. Treatment schedules 
along with doses, route and frequencies are summarized 
in Fig. 2a.
Fig. 2 Therapeutic response in PACC PDTX mouse model. a Reference table for chemotherapy doses along with route and treatment schedule. b 
Groups 1 to 9 mean volumes ± standard error (SEM) were plotted as a function of time. c Groups 1 to 9 median tumor volumes were plotted as a 
function of time. Tumor growth was continually observed after treatment regimen ceased. When an animal exited the study due to tumor size, the 
final tumor volume recorded for the animal was included with the data to calculate the mean and median volume at subsequent time points as 
indicated by dashed lines
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Schedules and dosing represent a blend of the maxi-
mally effective dose and/or maximally tolerated dose 
based on several experiments conducted by Charles River 
Discovery. Doses are in a range that reflects preclinical 
studies that have been seen previously in the literature 
[25–33].
Tumor growth was monitored individually even after 
therapy regimen was concluded and allowed to grow to 
an endpoint of 650–800 mm3or up to 74 days. This strat-
egy tested the therapy durability of the antitumor activity 
in order to determine “time-to-endpoint” (TTE). A group 
was terminated once the tumor burden reached endpoint 
or if fewer than 50 % of the assessable animals in a group 
remained on study. When individual mice were exited 
from the study due to “treatment-related” (TR) deaths, 
the final tumor volume recorded for the animal was 
included with the data to calculate the mean and median 
tumor volume at subsequent time points as indicated by 
dashed lines seen in Fig.  2b, c. Tumor growth volumes 
were excluded for deaths assessed as “non-treatment 
related” (NTR). Sample size (n) was adjusted in the event 
of NTR deaths (Fig. 2; Table 1).
Plotting both mean and median tumor volume for each 
treatment group revealed that imatinib had no effect on 
tumor growth with a TTE of 33.3  days as compared to 
placebo with a TTE of 32.7 days. T-C was only 0.6, which 
is the “difference between the median TTE of treated 
group vs. placebo control”. Irinotecan (T-C = 8.1), gem-
citabine (T-C =  5.1), and 5-FU (T-C =  4.6) maintained 
a strong response while on therapy, but the tumor rap-
idly grew once the drug was discontinued. Erlotinib 
(T-C =  21.7), bevacizumab (T-C =  36.1) and liposomal 
doxorubicin (T-C  =  33.1) maintained an intermedi-
ate response during therapy and tumor volume slowly 
increased over time. By far, the most effective agent was 
oxaliplatin which sustained a strong anti-tumor response 
for the entire course of this study (74  days) with only 3 
weekly treatments (Fig.  2; Table  1). Statistical signifi-
cance was evaluated by log rank test and overall both 
oxaliplatin (P =  0.0001) and bevacizumab (P =  0.0413) 
treatments demonstrated significant anti-tumor activ-
ity while liposomal doxorubicin was considered trending 
(P = 0.112). Erlotinib was also considered trending, but 
the data was not evaluable due to nadir from toxicities 
with body weight (BW) percent change of −15.3 % and 2 
TR deaths (Table 1).
Serum lipase levels correlate with response 
to chemotherapy
Serum lipase levels were monitored on the blood of the 
xenografts to examine pancreatic lipase secretion com-
pared to tumor volume [20]. On day 15, a positive cor-
relation among the groups between serum lipase levels 
and tumor volumes in the xenografts was observed with 
R2 = 0.6949 (Fig. 3a). Among the groups, lipase secreted 
into serum (day 15) was only able to significantly decrease 
following oxaliplatin treatment (P = 0.046), reaching lev-
els below pre-treatment. Bevacizumab treatment also led 
Table 1 Result summary of PA-018 therapeutic responses and toxicities
The therapies used included DNA synthesis inhibitors (5-FU, gemcitabine), a DNA alkylating agent (oxaliplatin), a DNA intercalating agent (liposomal doxorubicin), a 
topoisomerase inhibitor (irinotecan), an EGFR inhibitor (erlotinib), a c-kit inhibitor (imatinib) and an angiogenesis inhibitor (bevacizumab). Therapies were delivered as 
indicated and tumor growth was continually observed after treatment regimen ceased in order to determine time-to-endpoint (TTE) and difference between median 
TTE of treated groups vs. placebo (T-C). Statistical significance was evaluated by logrank test, df = 1 with significance indicated by * and non-significance (ns) or not 
evaluable (ne). Body weight (BW) nadir was shown as percent change and deaths were divided into treatment-related deaths (TR) and non-treatment related deaths 
(NTR). The final sample size (n) was calculated by removing NTR deaths
n number of animals in a group not dead from accidental or unknown causes, or euthanized for sampling, TTE time to endpoint, T-C difference between median TTE 
(days) of treated group versus control group, TR treatment-related death, NTR non-treatment-related death, Mean BW Nadir lowest group mean body weight, as  % 
change from day 1, ne not evaluable, ns not significant
Statistical significance (Logrank test, df = 1): * P < 0.05, ** P < 0.01, *** P < 0.001, compared to Group 1
a Time of sacrifice (74 days) was artificially used at TTE for oxaliplatin group
Group N Treatment regimen Median Statistical significance Mean BW Deaths
Agent mg/kg Route Schedule TTE TGD (T-C) Chi square P value Summary Nadir TR NTR
1 10 placebo – – – 32.7 – – – – −0.1 % day 14 0 0
2 10 5‑FU 100 ip qwk × 3 37.3 4.6 0.3966 0.5288 ns −5.9 % day 21 1 0
3 10 irinotecan 100 ip qwk × 3 40.8 8.1 0.5419 0.4616 ns −7.9 % day 21 0 0
4 10 oxaliplatin 10 ip qwk × 3 74* 41.3* 14.82 0.0001 *** −9.8 % day 21 0 0
5 10 gemcitabine 120 ip q3d × 4 37.8 5.1 1.265 0.2607 ns −5.2 % Day 39 1 0
6 9 bevacizumab 5 ip biwk × 5 68.8 36.1 4.165 0.0413 a −4.3 % day 21 0 1
7 9 erlotinib 80 po qd × 15 54.4 21.7 1.277 0.2585 ne −15.3 % day 14 2 1
8 10 doxorubicin 3 iv qwk × 3 65.8 33.1 2.525 0.112 ns −5.1 % day 42 0 0
9 9 imatinib 100 po qd × 28 33.3 0.6 0.09389 0.7593 ns −0.8 % day 21 0 1
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to lower serum lipase levels as compared to placebo, but 
it was not significant (P = 0.079). Of the eight monother-
apies, only 5-FU and imatinib were unable to decrease 
serum lipase levels as compared to the placebo control 
(Fig. 3b).
Endpoint therapeutic evaluation of proliferation, tumor 
vascularity, and apoptosis shows that oxaliplatin induces 
cell death in PACC
The endpoint tumors were analyzed via IHC for prolifera-
tion (Ki-67), tumor vascularity (CD31) and programmed 
cell death (cleaved caspase 3, CC3). Ki-67 percent posi-
tive expression remained similar in all treatment groups, 
which suggested that proliferation was similar at the time 
of collection (Fig. 4a). CD31 percent positive expression 
was increased in oxaliplatin, erlotinib, and doxorubicin 
groups as compared to placebo control, but only erlo-
tinib treatment was statistically significant (P  =  0.044) 
(Fig.  4b). On the other hand, CC3 staining significantly 
increased only in the oxaliplatin treated tissue compared 
to placebo control (P = 0.019) (Fig. 4c, d).
Oxaliplatin induces change in PACC morphology 
and re-expression of digestive enzymes
In further examination of oxaliplatin’s effects, micro-
scopic analysis showed that there was an increase in cyto-
plasmic content as well as cytoplasmic size as compared 
with placebo controls (Fig.  5a, panel i). Along with the 
histological changes, there was also a significant increase 
(P < 0.05) in cytoplasmic retention of amylase and lipase 
in the oxaliplatin treated tumors similar to normal pan-
creas (Fig. 5a panel ii, iii, b). We also noted that expres-
sion of collagen I was upregulated in certain portions of 
the oxaliplatin treated tissue when compared to placebo. 
Collagen I expression had been previously shown to be 
sparsely expressed around the borders of normal acinar 
cells and ducts [34, 35]. The Collagen I staining resembles 
the expression pattern of normal tissue in certain areas 
(Additional file 2: Figure S1).
Gene analysis together with immunofluorescence (IF) 
and IHC indicates that the PACC patient and PA-018 PDTX 
model have a BRCA2 mutation
An IF and IHC panel for BRCA1 and BRCA2 expression 
was performed on normal pancreas, pancreatic ductal 
adenocarcinoma (PDAC), and the PACC PDTX model. 
Both techniques demonstrate that nuclear BRCA1 is 
present in all tissue samples along with some cytoplas-
mic expression (Fig.  6a panel i; Additional file  3: Figure 
S2 panel i). Immunofluorescence shows that the PDTX 
model has no co-localization of BRCA2 and DAPI 
nuclear stain (Fig. 6a, panel ii). IHC on patient PACC tis-
sue and its PDTX (PA-018) also show a lack of BRCA2 
nuclear expression. Instead, only cytoplasmic expres-
sion in the islets and PACC tissue were observed (Addi-
tional file 3: Figure S2 panel ii). Mutational gene analysis 
of PA-018 PDX tissue was used to identify a 5 base pair 
deletion in BRCA2 (c.1755_1759del5) (Fig.  6b; Addi-
tional file  4: Figure S3). All sequence reads contained 
the mutated allele, indicating that there was no wild type 
BRCA2 allele present. This suggests a loss of heterozygo-
sity (LOH) occurred in the tumor.
Discussion
The rarity of pancreatic acinar cell carcinoma (PACC) 
has contributed to the lack of an effective standard treat-
ment for this deadly disease. One way to understand a 
disease and test potential treatments is to have an in vivo 
laboratory model. To date, only a few recorded studies 
have been able to recapitulate PACC in mice. The old-
est PACC model was formed by creating a transgenic 
mouse that expresses the transforming gene (T-antigen) 
Fig. 3 Evaluation of serum lipase enzyme levels. a Correlation plot of 
individual serum lipase levels compared to tumor volume indicated 
positive correlation with R2 = 0.6949 at day 15 when all groups were 
actively receiving chemotherapeutics. b Serum analysis for lipase 
secretion was performed on blood collected at pre‑dose, and day 
15. Data was plotted as mean ± standard deviation, n = 5. Asterisk 
indicated P < 0.05 for treatment group compared to placebo, n = 5. 
Erlotinib was not evaluable (ne) due to n = 3
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of the SV40 virus under the control of elastase I, a pan-
creas specific promoter [36]. This model had been modi-
fied to express luciferase to record tumor burden and can 
be used to test chemotherapeutics [2]. Recently, another 
mouse model had been made by deleting a gene that 
blocked mTOR signaling [37]. The importance of mTOR 
was corroborated by the decreased tumor burden in both 
of these PACC mouse models when treated with rapamy-
cin [2, 37]. While genetically engineered mouse models 
(GEMM)s was one approach to a successful model sys-
tem, the generation of PDTXs hold unique benefits as 
well.
Within cancer, tumor heterogeneity exists and there 
may be multiple ways the same kind of cancer can arise 
[38, 39]. By creating PDTX models we can learn the simi-
larities and differences between tumors that arose from 
different patients. We are also able to test tumors that 
have become chemoresistant to specific compounds and 
uncover possible alternatives [40, 41]. Thus, PDTXs pro-
vide representative signaling involved in disease progres-
sion and therapeutic responses that recapitulate those 
seen in patients [39, 42–47]. This is a report of the first 
fully characterized humanized model of PACC. Our 
in vivo model of human PACC can provide a novel means 
to further investigate the genetic and cellular mechanisms 
of this disease. Hence, we confirmed that the PDTX 
tumors were composed of human acinar cell carcinoma 
cells via STR profile, corroboration of biomarker expres-
sion seen in PACC patient tissues [15–18] and secretion 
of lipase into the bloodstream [14, 48] (Additional file 1: 
Table S1; Figs.  1, 3). With this data, we concluded that 
the PDTX tumor model (PA-018) was representative of 
our patient’s PACC, which provided the rationale for us 
to test multiple monotherapies based upon the patient’s 
Fig. 4 Endpoint therapeutic effects on proliferation, tumor vascularity, and apoptosis. a Ki67 for proliferation index was scored by positive counts 
per core section and plotted as mean percent positive ± standard deviation with no change observed at endpoint. b CD31 for blood vessel 
density was scored by positive pixel count over area and plotted as mean percent ± standard deviation, only erlotonib had a significant change 
observed at endpoint (P = 0.44). c Cleaved caspase‑3 (CC3) for apoptotic index was scored by positive pixel count over area and plotted as mean 
percent ± standard deviation. Oxaliplatin treatment yielded significant apoptosis (P = 0.0109) compared to placebo. d Representative CC3 IHC was 
shown for placebo and oxaliplatin groups. Asterisk indicated P < 0.05 for treatment group as compared to placebo, n = 5
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past treatment history as well as gene array and protein 
expression data [20] (Fig. 2).
Imatinib showed little response in PA-018, this mim-
icked the mixed and only transient clinical response 
to imatinib in the patient [20]. Liposomal doxorubicin 
(Doxil) led to significant tumor shrinkage of multi-
ple tumors in the liver of the patient, with a decrease in 
serum lipase and improvement in his quality of life [20]. 
Treatment was stopped due to known cardiac toxicity of 
doxorubicin and the patient’s cancer progressed. Simi-
larly, the PDTX model demonstrated growth inhibition 
to liposomal doxorubicin but the overall outcome was 
not significant (P = 0.112) due to the tumor growing back 
after treatment ended (Fig. 2; Table 1). Bevacizumab, an 
angiogenesis inhibitor was briefly administered after the 
patient’s metastatic disease had progressed but due to 
symptoms of confusion, the therapy was discontinued 
before the efficacy of the drug could have been assessed. 
In this study, we saw a statistically significant time to end 
point tumor volume (TTE) of bevacizumab treated mice 
(P = 0.0413) (Fig. 2; Table 1). These data leaves open the 
possibility of bevacizumab as an effective chemotherapy.
We aimed to test standard treatments along with new 
rationally designed monotherapies. 5-FU and gemcit-
abine have both been clinically recommended chemo-
therapeutics for pancreatic cancer [49] and were added 
to this study to compare with drugs administered to 
the PA-018 patient. These two treatments were unable 
to maintain tumor reduction and were only better than 
imatinib (Fig. 2; Table 1). From our previous PACC study, 
we measured RNA levels of the PA-018 tumor biopsy and 
saw 2.5 fold elevated increase in TOPO1 which can be 
targeted by irinotecan [20]. As expected, irinotecan dem-
onstrated a strong response while on therapy in PA-018, 
but off therapy the tumor continued to grow. EGFR 
expression was also elevated, so erlotinib was tested 
[20]. There were too many treatment related deaths to 
truly evaluate this data group. A lower dose of the drug 
may have to be considered in future exams. The most 
significant response in the PDTX model was observed 
Fig. 5 Oxaliplatin induces change in morphology and re‑expression of digestive enzymes. a H&E depicted morphological changes and increased 
cell size in PA‑018 after oxaliplatin treatment on endpoint tumor sections. There was also cytoplasmic retention of the digestive enzymes, amylase 
and lipase. Representative IHC was shown for placebo and oxaliplatin groups. Inlays are normal human pancreas. b Cytoplasmic amylase and lipase 
were quantitated by positive pixel count over area and plotted as mean ± standard deviation. **P < 0.01 for treatment group as compared to 
placebo, n = 5
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following oxaliplatin treatment, which prevented tumor 
growth weeks after treatment cessation, leading to a 
durable response (Fig. 2; Table 1). Indeed, oxaliplatin was 
the only compound to significantly induce apoptosis in 
the PACC model (Fig. 4).
Like other platinum compounds, oxaliplatin inhibits 
DNA synthesis by forming both inter- and intra-strand 
cross links in DNA which prevent DNA replication and 
transcription, causing cell death [50]. Oxaliplatin is used 
for treatment of colorectal cancer when it is administered 
in combination with folinic acid and 5-fluorouracil, (FOL-
FOX) [51]. In addition, the standard of care for advanced 
pancreatic cancer is currently FOLFIRINOX (5-FU/folinic 
acid, irinotecan, and oxaliplatin) [52]. We pursued the 
beneficial effects of oxaliplatin treatment and observed 
that the PACC tissue retained amylase and lipase in the 
cytoplasm and stopped releasing lipase into the blood 
stream (Figs.  3b, 5). Serum lipase levels can be moni-
tored in the blood as a measure of tumor burden with the 
expectation that the higher the value, the larger the tumor 
burden [20]. Serum samples from oxaliplatin treated 
mice were significantly decreased at day 15 of treatment 
as compared to the placebo controls (Fig. 3b). These data 
showed that it is not lipase production but lipase secre-
tion that is indicative of disease, since normal pancreas 
accumulates lipase in the cytoplasm (Fig.  5a, panel iii) 
Fig. 6 Immunofluorescence and genetic analysis indicates a BRCA2 mutation in the PA‑018 PAAC model. a Immunofluorescence staining for 
BRCA1 and BRCA2. Panel i shows BRCA1 (red) expressed throughout the nucleus and cytoplasm in normal, PDAC, and the PAAC PDTX tissue. In 
panel ii, normal and PDAC tissue show co‑localization of nuclear DAPI stain and BRCA2 but the PAAC PDTX tissue, does not have this co‑localization, 
indicating that BRCA2 expression is confined to the cytoplasm. b Gene mutational analysis of BRCA2 confirms the presence a 5 base pair deletion 
on exon 10
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but barely secretes it [11]. By the end of the study, tissue 
morphology of oxaliplatin treated mice showed that the 
cancer cells became larger and resembled normal aci-
nar cells more than PACC tissue (Fig. 5a panel i). Indeed, 
platin drugs have been reported to induce differentiation 
in cancer cells both in vitro and in vivo [53, 54]. Our data 
indicates that oxaliplatin inhibits PACC tumor growth 
by inducing re-differentiation and promoting apoptosis 
(Figs.  4c, d, 5). Next we assessed why our PACC PDTX 
model responded well to oxaliplatin.
Previous literature has shown that the presence of 
BRCA mutations (mutations in a gene involved in DNA 
repair) in both breast and ovarian cancers are associ-
ated with increased sensitivity to platinum compounds 
[55–57]. This sensitivity has also been shown in ovarian 
tumors with either germline or sporadic somatic muta-
tions [57]. Furthermore, within the small subset of PDAC 
patients carrying germline BRCA gene mutations, those 
treated with platinum compounds had an increase in 
overall survival [58]. These findings are of particular 
interest because genomic profiling on 44 PACC patient 
tumors uncovered DNA repair mutations in 45 % of the 
samples [19]. In our PDTX model, BRCA1 was mostly 
localized in the nucleus, while BRCA2 was mostly local-
ized in the cytoplasm and absent from the nucleus, which 
suggests that the protein is truncated and lost its nuclear 
localization sequence [59, 60] (Fig. 6a; Additional file 3: 
Figure S2). The BRCA2 truncation prevents the cell from 
entering the nucleus and taking part in the DNA homolo-
gous recombination repair pathway [57]. Mutational gene 
analysis of BRCA2 confirms that a 5 base pair deletion 
on exon 10 (c.1755_1759del5) was present in our PDX 
model (Fig.  6b). BRCA2 deletions have frequently been 
associated with deleterious protein truncations [61, 62]. 
The same gene deletion (referred by the Breast Cancer 
Information Core as 1983del5) has even been reported 
as a familial BRCA2 mutation [63]. Using this evidence, 
we concluded that a BRCA2 truncation mutation may be 
one potential reason our PACC model was sensitive to 
oxaliplatin induced cell death. Indeed, previous literature 
has reported case of a PACC patient with a hereditary 
BRCA2 mutation. The individual was on a combination 
of gemcitabine and oxaliplatin, which prolonged their 
survival, several years longer than the average life expec-
tancy of PACC patients [64]. Overall, previous findings 
together with our data suggest that oxaliplatin may be 
beneficial to PACC patients whose tumors carry DNA 
repair mutations, such as BRCA2.
Conclusions
In summary, it was supported that this newly character-
ized PACC PDTX model first recapitulated the mono-
therapy response seen in its matching patient tissue and 
in the process secondly discovered that oxaliplatin was 
very effective as a monotherapy in this PACC model. 
Because of the rarity of PACC, only a handful of retro-
spective articles and case reports describing experimen-
tal therapy have been published. Our findings involving 
oxaliplatin in this PDTX model warrant further evalu-
ation for the management of pancreatic acinar cell car-
cinoma. As the first and only preclinical human PACC 
derived model, the scientific community can use it to bet-
ter understand the pathobiology of this disease.
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